An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat

Journal of Clinical Pharmacology

Volumn 49, Issue 5, 2009, Pages 606-612

  Connor, Alyson ^a   Evans, Phil ^a   Doto, Judy ^b   Ellis, Corey ^b   Martin, David E ^b,c  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

^b 209 Perry Pkwy Gaithersburg M   (United States)

^c 23801 Echo Creek Court   (United States)

Author keywords

Bevirimat; Enteriong; HIV; Pharmacokinetics; Regional bioavailability

Indexed keywords

BEVIRIMAT;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG CAPSULE; DRUG DELIVERY SYSTEM; FEMALE; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRACT SCINTISCANNING; HUMAN; MALE; MEMBRANE PERMEABILITY; MICROCAPSULE; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINE; TABLET FORMULATION; TIMED DRUG RELEASE;

ADULT; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CAPSULES; COLON; CROSS-OVER STUDIES; DOSAGE FORMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ILEUM; INTESTINAL ABSORPTION; JEJUNUM; MALE; SUCCINATES; TRITERPENES;

EID: 65449132359     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009333488     Document Type: Article

References (10)

1. Richmann DD, Bozzette S., Morton S., et al. The prevalence of antiretroviral drug resistance in the US. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001 ; Chicago, Ill. Abstract LB-17. 2. LaBonte J., Lebbos J., Kirkpatrick P. Enfuvirtide. Nature Reviews. Drug Discovery. 2003 ; 5: 345-346.
2. Grant RM, Hecht FM, Warmerdam M., et al. Time trends in primary HIV-1 drug resistance among recently infected persons. Journal of the American Medical Association. 2002 ; 288: 181-188. (Pubitemid 34755278)
3. Li F., Goila-Gaur R., Salzwedel K., et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proceedings of the National Academy of Sciences U S A. 2003 ; 100: 13555-13560. (Pubitemid 37444780)
4. Wen Z., Martin DE, Bullock P., Lee KH, Smith PC Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP- glucuronosyltransferases and species differences. Drug Metabolism & Disposition. 2007 ; 35: 440-448. (Pubitemid 46333907)
5. Wilding IR, Hirst PH, Connor AL Development of new engineering-based capsule for human drug absorption studies. Pharmaceutical Science and Technology Today. 2000 ; 3: 385-392.
6. Wilding IR, Prior, DV Remote controlled capsules in human drug absorption (HDA) studies. Critical Reviews in Therapeutic Drug Carrier Systems. 2003 ; 20: 405-431. (Pubitemid 41646574)
7. Martin DE, Blum R., Wilton J., et al. Safety and pharmacokinetics of bevirimat (PA-57), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrobial Agents and Chemotherapy. 2007 ; 51: 3063-3066. (Pubitemid 350067509)
8. Martin NE, Collison KR, Martin LL, et al. Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers. Journal of Clinical Pharmacology. 2003 ; 43: 529-538. (Pubitemid 36506154)
9. Oo C., Snell P., Barrett J., Dorr A., Liu B., Wilding IR Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules. International Journal of Pharmaceutics. 2003 ; 257: 297-299. (Pubitemid 36507055)
10. Hinderling PH, Karara AH, Tao B., Pawula M., Wilding IR, Lu M. Systemic availability of the active metabolite hydroxyl-fasudil after administration of fasudil to different sites of the human gastrointestinal tract. Journal of Clinical Pharmacology. 2007 ; 47: 19-25.